Recent Advances in Technologies Directed against Dendritic Cells for Cancer Management

Share this:
Published: 17 Nov 2017

This edition of the Genetic Technology TOE profiles using dendritic cells for cancer management. The role of miRNA-128 in enhancing the anti-cancer functions of dendritic cells, lentiviral vectors that target dendritic cells, siRNA targeting dendritic cells, and dendritic cells targeting peptide are presented. The corresponding clinical trials scenario for dendritic cells targets is also depicted. The Genetic Technology TechVision Opportunity Engine (TOE) presents the latest R&D developments and advances with an emphasis on opportunities to profit in the explosive field of genetic technology through technology transfer, joint ventures, and acquisitions. The complete gamut of genetic technology applications is covered including the latest developments in omics technologies; genetic, cellular, and alternative therapies; sequencing technologies; and genetically altered animals and plants. The Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare. Keywords: Dendritic cell targets, cancer management, miRNA-128, siRNA, lentiviral vectors



Features of this research


Help Desk

Full list of offices

For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..